Telitacicept not checked
Vor Biopharma · RC18 · RC18-L
FollowEvery change as it happens, and a Monday email
Trials
2 active
4 in total · 4 in the EU
What this is
- How it works
- A decoy protein that soaks up a signal molecule before it can reach the body's cells.-cept: receptor molecules, native or modified WHO name stem
- Main trialPhase 3
- “The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.”In the company’s words, NCT06456580 on ClinicalTrials.gov
- Other names
- RC18 · RC18-L
Other drugs for Generalized Myasthenia Gravis
- GefurulimabAlexion Pharmaceuticals, Inc. · Phase 3
- B007Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 2/3
- Descartes-08Cartesian Therapeutics · Phase 3
- TelitaciceptRemeGen · Phase 3
- Efgartigimodargenx · Phase 3
- IptacopanNovartis · Phase 3
Coming up2
- Mar 2027Phase 3 trial completes · ClinicalTrials.gov
- Dec 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Mar 2027 | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | |
| Phase 3Recruiting | Dec 2028 | Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease | |
| Phase 3Withdrawn | 2 Jan 2025 | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2) | |
| Phase 3Terminated | 6 Jan 2025 | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026